CA2393730A1 - Hla class i a2 tumor associated antigen peptides and vaccine compositions - Google Patents

Hla class i a2 tumor associated antigen peptides and vaccine compositions Download PDF

Info

Publication number
CA2393730A1
CA2393730A1 CA002393730A CA2393730A CA2393730A1 CA 2393730 A1 CA2393730 A1 CA 2393730A1 CA 002393730 A CA002393730 A CA 002393730A CA 2393730 A CA2393730 A CA 2393730A CA 2393730 A1 CA2393730 A1 CA 2393730A1
Authority
CA
Canada
Prior art keywords
seq
peptide
epitope
hla
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002393730A
Other languages
English (en)
French (fr)
Inventor
John Fikes
Alessandro Sette
John Sidney
Scott Southwood
Esteban Celis
Elissa Keogh
Robert Chesnut
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/543,608 external-priority patent/US6602510B1/en
Application filed by Individual filed Critical Individual
Publication of CA2393730A1 publication Critical patent/CA2393730A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103Receptors for growth factors
    • A61K39/001106Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001148Regulators of development
    • A61K39/00115Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151Apoptosis related proteins, e.g. survivin or livin p53
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00118Cancer antigens from embryonic or fetal origin
    • A61K39/001182Carcinoembryonic antigen [CEA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001184Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4615Dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/462Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622Antigen presenting cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70539MHC-molecules, e.g. HLA-molecules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CA002393730A 1999-12-13 2000-12-13 Hla class i a2 tumor associated antigen peptides and vaccine compositions Abandoned CA2393730A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US17044899P 1999-12-13 1999-12-13
US60/170,448 1999-12-13
US09/543,608 2000-04-05
US09/543,608 US6602510B1 (en) 2000-04-05 2000-04-05 HLA class I A2 tumor associated antigen peptides and vaccine compositions
US58320000A 2000-05-30 2000-05-30
US09/583,200 2000-05-30
PCT/US2000/034318 WO2001041741A1 (en) 1999-12-13 2000-12-13 Hla class i a2 tumor associated antigen peptides and vaccine compositions

Publications (1)

Publication Number Publication Date
CA2393730A1 true CA2393730A1 (en) 2001-06-14

Family

ID=27389823

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002393730A Abandoned CA2393730A1 (en) 1999-12-13 2000-12-13 Hla class i a2 tumor associated antigen peptides and vaccine compositions

Country Status (5)

Country Link
EP (1) EP1242049A4 (de)
JP (1) JP2003516344A (de)
AU (1) AU2273701A (de)
CA (1) CA2393730A1 (de)
WO (1) WO2001041741A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2420225A1 (en) * 2000-09-01 2002-03-14 Epimmune Inc. Hla-a2.1 binding peptides and their uses
US20060094649A1 (en) * 2002-12-10 2006-05-04 Keogh Elissa A Hla-a1,-a2,-a3,-a24,-b7, and-b44 tumor associated antigen peptides and compositions
EP1903056A3 (de) * 2002-12-10 2008-05-07 Idm Pharma, Inc. HLA-A1, -A2, -A3, -A24, -B7 and -B44 bindende Peptide die Tumorassoziiert-Antigen Epitopen enthalten, und Zusammensetzungen davon
MXPA05006113A (es) * 2002-12-11 2005-09-30 Pharmexa As Epitopos sencillos objetivo.
CA2522812C (en) * 2003-04-18 2012-08-21 Idm Pharma, Inc. Hla-a2 tumor associated antigen peptides and compositions
US7939090B2 (en) 2003-10-21 2011-05-10 Cedars-Sinai Medical Center System and method for the treatment of cancer, including cancers of the central nervous system
EP2084267B1 (de) 2006-09-26 2018-04-11 Cedars-Sinai Medical Center Krebsstammzellen-antigen-impfstoffe und entsprechende verfahren
US8871211B2 (en) 2006-09-28 2014-10-28 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
EP2215111B1 (de) * 2007-11-01 2016-03-16 Mayo Foundation For Medical Education And Research Hla-dr-bindende peptide und deren anwendungen
EP2328923B1 (de) 2008-09-02 2016-01-13 Cedars-Sinai Medical Center Cd133-epitope
EP2391635B1 (de) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr-bindende polypeptide und verwendungen davon
AU2010232512B2 (en) * 2009-04-01 2013-07-18 University Of Miami Vaccine compositions and methods of use thereof
DK2427485T3 (en) 2009-05-07 2017-03-13 Immunocellular Therapeutics Ltd CD133 epitopes
US10076491B2 (en) 2013-02-05 2018-09-18 Nitto Denko Corporation Vaccine composition
US20140220058A1 (en) * 2013-02-05 2014-08-07 Nitto Denko Corporation Vaccine composition for transdermal or mucosal administration
WO2014127296A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd Cancer vaccines and vaccination methods
RU2627175C2 (ru) * 2013-03-08 2017-08-03 Тайхо Фармасьютикал Ко., Лтд. Новый пептид, имеющий 5 соединенных эпитопов ctl
JP6692294B2 (ja) 2013-07-31 2020-05-13 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーBioVentures, LLC 腫瘍関連糖鎖抗原を標的として癌を治療及び予防するための組成物及び方法
PL3061771T3 (pl) 2013-10-21 2020-10-19 Taiho Pharmaceutical Co., Ltd. Nowy peptyd o czterech połączonych epitopach dla ctl
GB201504502D0 (en) * 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
SG10202111399YA (en) 2015-12-22 2021-11-29 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201604458D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
US11447564B2 (en) 2017-04-26 2022-09-20 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69435292D1 (de) * 1993-03-05 2010-06-17 Epimmune Inc Verfahren zur herstellung von immunogenen hla-a2.1-bindenden peptiden
WO1998033888A1 (en) * 1997-01-31 1998-08-06 Epimmune, Inc. Peptides and peptide-loaded antigen presenting cells for the activation of ctl

Also Published As

Publication number Publication date
JP2003516344A (ja) 2003-05-13
AU2273701A (en) 2001-06-18
WO2001041741A1 (en) 2001-06-14
WO2001041741A9 (en) 2002-05-30
EP1242049A1 (de) 2002-09-25
EP1242049A4 (de) 2005-01-05

Similar Documents

Publication Publication Date Title
US6602510B1 (en) HLA class I A2 tumor associated antigen peptides and vaccine compositions
US20080279924A1 (en) HLA class I A2 tumor associated antigen peptides and vaccine compositions
US9913884B2 (en) HLA-A2 tumor associated antigen peptides and compositions
EP2089423B1 (de) Antigenspezifische multi-epitop-impfstoffe
CA2393730A1 (en) Hla class i a2 tumor associated antigen peptides and vaccine compositions
JP4776131B2 (ja) ヘテロクリティックアナログおよび関連方法
US20160022791A1 (en) Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of Cancer
US20060094649A1 (en) Hla-a1,-a2,-a3,-a24,-b7, and-b44 tumor associated antigen peptides and compositions
JP2003530083A (ja) ペプチドおよび核酸組成物を使用する、HER2/neuに対する細胞性免疫応答の誘導
US20030224036A1 (en) Hla class I a2 tumor associated antigen peptides and vaccine compositions
US20060018915A1 (en) Heteroclitic analogs and related methods
US9475841B2 (en) Melanoma antigen peptide and uses thereof
US9573975B2 (en) Melanoma antigen peptide and uses thereof
US20140147490A1 (en) Hla class i a2 tumor associated antigen peptides and vaccine compositions
EP1903056A2 (de) HLA-A1, -A2 -A3, -A24, -B7 und -B44-Tumor-assoziierte Antigenpeptide und -zusammensetzungen

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued